Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01866293 · OUTCOME

Maximally Tolerated Dose

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma · Source last updated 2017-08-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg
Interval / dispersion
Not reported
Time frame
1 year

What was measured

This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.

Analysis population: 9 participants are evaluable. 2 participants never started treatment.

Groups in this outcome

Cabozantinib (XL184)

Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cabozantinib (XL184)11

Reported measurements

Source class 1
Values in mg · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cabozantinib (XL184)40Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        40
denoms
  1. counts
    1. group Id
      OG000
      value
      11
    units
    Participants
description
This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
groups
  1. description
    Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
    id
    OG000
    title
    Cabozantinib (XL184)
param Type
NUMBER
population Description
9 participants are evaluable. 2 participants never started treatment.
reporting Status
POSTED
time Frame
1 year
title
Maximally Tolerated Dose
type
PRIMARY
unit Of Measure
mg

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice